Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib + Rituximab in R/R DLBCL with MYD88/CD79 Mutations
NCT04994626Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Oct 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of ibrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
ibrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04994626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04994626.